The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: Results from a nationwide cohort in Spain (LESIMAB)

Lupus

Volumn 23, Issue 10, 2014, Pages 1014-1022

  Fernandez Nebro A ^a   Marenco, J L ^b   Lopez Longo F ^c   Galindo, M ^d   Hernandez Cruz B E ^e   Narvaez J ^f   Rua Figueroa I ^g   Raya Alvarez, E ^h   Zea, A ⁱ   Freire, M ^j   Sanchez Atrio A I ^k   Garcia Vicuna R ^l   Pego Reigosa, J M ^m   Manrique Arija, S ^a   Nieves Martin L ^a   Carreno L ^c  

^a Institute of Biomedical Research in Malaga and BIONAND Nanomedicine Platform   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^h HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j HOSPITAL JUAN CANALEJO   (Spain)

^k HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^l HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^m UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

more..

Author keywords

Cohort; Lipid profile; Proteinuria; Refractory; Rituximab; Systemic lupus erythematosus

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; HIGH DENSITY LIPOPROTEIN; HYDROXYCHLOROQUINE; LIPID; LOW DENSITY LIPOPROTEIN; PREDNISONE; RITUXIMAB; STEROID; TRIACYLGLYCEROL; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DISEASE ACTIVITY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CLINICAL TRIAL; DYSLIPIDEMIAS; LONGITUDINAL STUDY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SPAIN; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL MARKERS; DYSLIPIDEMIAS; FEMALE; HUMANS; LINEAR MODELS; LIPIDS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84906715670     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314534909     Document Type: Article

References (35)

1. Liu Z Davidson A. Taming lupus-A new understanding of pathogenesis is leading to clinical advances. Nat Med 2012; 18: 871-882.
2. Manzi S Meilahn EN Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-415.
3. Jonsson H Nived O Sturfelt G. Outcome in systemic lupus erythematosus: A prospective study of patients from a defined population. Medicine (Baltimore) 1989; 68: 141-150.
4. Bessant R Hingorani A Patel L MacGregor A Isenberg DA Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43: 924-929.
5. Petri M Lakatta C Magder L Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. Am J Med 1994; 96: 254-259.
6. Carmona L Ferná ndez-Nebro A Gonzalez-Crespo R Maese J Nishishinya B. Meta-analysis of cardiovascular events in patients with rheumatic diseases using COX-2 inhibitors (not rofecoxib). Arthritis Rheum 2005; 52: S230.
7. Carmona L Descalzo MA Perez-Pampin E et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007; 66: 880-885.
8. Popa C van den Hoogen FH Radstake TR et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1503-1507.
9. Pego-Reigosa JM Lu TY Fontanillo MF del Campo-Pérez V Rahman A Isenberg DA. Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: A retrospective observational study. Rheumatology (Oxford) 2010; 49: 691-696.
10. Ferná ndez-Nebro A de la Fuente JL Carreno L et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: The LESIMAB study. Lupus 2012; 21: 1063-1076.
11. Charlson ME Pompei P Ales KL MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383.
12. Mancia G De Backer G Dominiczak A et al. ESH/ESC 2007 Guidelines for the management of arterial hypertension [article in Spanish]. Rev Esp Cardiol 2007; 60: 968.e961-e994.
13. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
14. Wilson PW D'Agostino RB Levy D Belanger AM Silbershatz H Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
15. Looney RJ Anolik JH Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
16. Sabahi R Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006; 66: 1933-1948.
17. Gladman D Ginzler E Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
18. Sarkissian T Beyene J Feldman B McCrindle B Silverman ED. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum 2007; 56: 631-638.
19. Borba EF Bonfá E. Dyslipoproteinemias in systemic lupus erythematosus: Influence of disease activity and anticardiolipin antibodies. Lupus 1997; 6: 533-539.
20. Ettinger WH Goldberg AP Applebaum-Bowden D Hazzard WR. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 1987; 83: 503-508.
21. Urquizu-Padilla M Balada E Chacon P Pérez EH Vilardell- Tarré s M Ordi-Ros J. Changes in lipid profile between flare and remission of patients with systemic lupus erythematosus: A prospective study. J Rheumatol 2009; 36: 1639-1645.
22. Formiga F Meco JF Pinto X Jacob J Moga I Pujol R. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 2001; 10: 359-363.
23. Borba EF Bonfá E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001; 28: 780-785.
24. Wallace DJ Metzger AL Stecher VJ Turnbull BA Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322-326.
25. Costenbader KH Wright E Liang MH Karlson EW. Cardiac risk factor awareness and management in patients with systemic lupus erythematosus. Arthritis Rheum 2004; 51: 983-988.
26. Lund FE Garvy BA Randall TD Harris DP. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005; 8: 25-54.
27. Silverman GJ Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003; 5(Suppl 4): S1-S6.
28. Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 1999; 107: 119-125.
29. Gonzalez-Gay MA De Matias JM Gonzalez-Juanatey C et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83-86.
30. Qin B Qiu W Avramoglu RK Adeli K. Tumor necrosis factoralpha induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein B48-containing lipoproteins. Diabetes 2007; 56: 450-461.
31. Beutler B Mahoney J Le Trang N Pekala P Cerami A. Purification of cachectin a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 1985; 161: 984-995.
32. Svenungsson E Gunnarsson I Fei GZ Lundberg IE Klareskog L Frostega? rd J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with upregulation of thetumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2533-2540.
33. Matsumura R Umemiya K Sugiyama T et al. Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: A prospective series of nine patients. Clin Exp Rheumatol 2009; 27: 416-421.
34. Wu T Xie C Wang HW et al. Elevated urinary VCAM-1 Pselectin soluble TNF receptor-1 and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 2007; 179: 7166-7175.
35. Lobo RA Skinner JB Lippman JS Cirillo SJ. Plasma lipids and desogestrel and ethinyl estradiol: A meta-analysis. Fertil Steril 1996; 65: 1100-1109.